Order Article Reprints

Dinh A, Bleibtreu A, Duran C, Bouchand F, Bosch A, Crozon-Clauzel J, Roncato-Saberan M, Matt M, Boibieux A, Fanton A, et al. National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa. Antibiotics. 2024; 13(12):1152. https://doi.org/10.3390/antibiotics13121152

Dinh, Aurélien, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton, and et al. 2024. "National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa" Antibiotics 13, no. 12: 1152. https://doi.org/10.3390/antibiotics13121152

Dinh, A., Bleibtreu, A., Duran, C., Bouchand, F., Bosch, A., Crozon-Clauzel, J., Roncato-Saberan, M., Matt, M., Boibieux, A., Fanton, A., Wille, H., Fiaux, E., Pilmis, B., Lacoste, M., Saint-Genis, Q., Thumerelle, C., Pavese, P., Vuotto, F., Senneville, E., ... on behalf of the Meropenem-Vaborbactam French Study Group. (2024). National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa. Antibiotics, 13(12), 1152. https://doi.org/10.3390/antibiotics13121152